Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxyphenbutazone Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 2/20 | 0.97 |
| ▸ | LMNA | P02545 | 3/20 | 0.97 |
| ▸ | RAB9A | P51151 | 3/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.97 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.97 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.97 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.97 |
| ▸ | TP53 | P04637 | 1/20 | 0.97 |
| ▸ | MAPT | P10636 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.97 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 6/20 | 0.41 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Oxyphenbutazone Anhydrous SCHEMBL25854 | 1.00 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL2525061 | 1.00 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL1263243 | 0.99 | LMNA (0.94) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL25856 | 0.99 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL5316370 | 0.99 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL25857 | 0.99 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL11337449 | 0.99 | LMNA (1.00) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL1263248 | 0.97 | LMNA (0.97) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL28278628 | 0.96 | LMNA (0.94) | LMNARAB9AALDH1A1CYP3A4PTGS1 | |
| Oxyphenbutazone Anhydrous SCHEMBL5612853 | 0.94 | LMNA (0.92) | LMNARAB9AALDH1A1CYP3A4PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7663000-B2 | cytosine suppressive antiinflammatory agents; viricides; immunomodulators | A-VIRAL ASA (NO) | 2010-02-16 | — | — | US | disclosed |
| US-20080287390-A1 | Pyrazolidinol compounds | A-VIRAL AS (NO) | 2008-11-20 | — | — | US | disclosed |
| US-20080262068-A1 | Method of Tonic Treatment With Oxyphenbutazone Derivatives | A-VIRAL ASA (NO) | 2008-10-23 | — | — | US | disclosed |
| US-20070155812-A1 | Thio-substituted phenbutazone compounds as anti-inflammatory, anti-viral and immunomodulatory agents | DEKKERS DAVID W C | 2007-07-05 | — | — | US | disclosed |
| US-20070112072-A1 | Quinoneimines of malonic acid diamides | A-VIRAL ASA (NO) | 2007-05-17 | — | — | US | disclosed |
| US-20070037772-A1 | Pyrazolidinol compounds | A-VIRAL AS (NO) | 2007-02-15 | — | — | US | disclosed |
| EP-1750692-A2 | METHOD OF TONIC TREATMENT WITH OXYPHENBUTAZONE DERIVATIVES | A-Viral ASA (NO) | 2007-02-14 | — | — | EP | disclosed |
| EP-1651212-A1 | THIO-SUBSTITUTED PHENBUTAZONE COMPOUNDS AS ANTI-INFLAMMATORY, ANTI-VIRAL AND IMMUNOMODULATORY AGENTS | A-Viral ASA (NO) | 2006-05-03 | — | — | EP | disclosed |
| EP-1651203-A1 | QUINONEIMINES OF MALONIC ACID DIAMIDES | A-Viral ASA (NO) | 2006-05-03 | — | — | EP | disclosed |
| EP-1194409-B1 | PYRAZOLIDINOL COMPOUNDS | VIRAL ASA A (NO) | 2006-02-01 | — | — | EP | disclosed |
| WO-2005107748-A2 | METHOD OF TONIC TREATMENT WITH OXYPHENBUTAZONE DERIVATIVES | A-VIRAL ASA (NO) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005011679-A1 | THIO-SUBSTITUTED PHENBUTAZONE COMPOUNDS AS ANTI-INFLAMMATORY, ANTI-VIRAL AND IMMUNOMODULATORY AGENTS | A-VIRAL ASA (NO) | 2005-02-10 | — | — | WO | disclosed |
| WO-2005011664-A1 | QUINONEIMINES OF MALONIC ACID DIAMIDES | A-VIRAL ASA (NO) | 2005-02-10 | — | — | WO | disclosed |
| US-6852749-B1 | Pyrazolidinol compounds | A-VIRAL AS (NO) | 2005-02-08 | — | — | US | disclosed |
| US-20040152751-A1 | Pyrazolidinol compounds | TJOTTA ENOK (NO) | 2004-08-05 | — | — | US | disclosed |
| EP-1194409-A1 | PYRAZOLIDINOL COMPOUNDS | A-Viral AS (NO) | 2002-04-10 | — | — | EP | disclosed |
| EP-1140075-A1 | TREATMENT OF RETROVIRAL INFECTIONS WITH OXYPHENBUTAZONE | A-Viral AS (NO) | 2001-10-10 | — | — | EP | disclosed |
| WO-2001000585-A1 | PYRAZOLIDINOL COMPOUNDS | A-VIRAL AS (NO) | 2001-01-04 | — | — | WO | disclosed |
| WO-2000038679-A1 | TREATMENT OF RETROVIRAL INFECTIONS WITH OXYPHENBUTAZONE | A-VIRAL AS (NO) | 2000-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262068-A1 | Method of Tonic Treatment With Oxyphenbutazone Derivatives | HTT, NFATC1, BACH1 | PTGS1 658/4885LMNA 3740/4885RAB9A 2878/4885 |
| US-20080287390-A1 | Pyrazolidinol compounds | NOX5, TPMT, ICOS | PTGS1 205/4885LMNA 4868/4885RAB9A 4507/4885 |
| US-20070155812-A1 | Thio-substituted phenbutazone compounds as anti-inflammatory, anti-viral and immunomodulatory agents | MSR1, CD4, SSB | PTGS1 23/4885LMNA 4693/4885RAB9A 4342/4885 |
| US-20070037772-A1 | Pyrazolidinol compounds | NOX5, TPMT, ICOS | PTGS1 205/4885LMNA 4868/4885RAB9A 4507/4885 |
| US-20040152751-A1 | Pyrazolidinol compounds | NOX5, TPMT, ICOS | PTGS1 205/4885LMNA 4868/4885RAB9A 4507/4885 |
| US-20070112072-A1 | Quinoneimines of malonic acid diamides | SQOR, MDH2, ME3 | PTGS1 846/4885LMNA 4608/4885RAB9A 1194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.